The latter finding was, in fact, the basis of a small clinical trial where immunization of glioma patients with autologous glioma cells expressing antisense IGF-IR had a beneficial effect, resulting in clinical and radiographic improvements in 8 of 12 patients, including three spontaneous or postsurgical regressions at either the primary or a distant intracranial site (49). The gene discussed is IGF1R; the disease is central nervous system cancer.